US › Healthcare

Abeona Therapeutics Inc (ABEO)

US · Healthcare · Biotechnology

$4.43-4.73%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$11.4M

Revenue YoY

+2745.0%

Net profit

$-20.2M

Profit YoY

-118.6%

EPS

$-0.35

EPS estimate

$-0.23

Net margin

-177.4%

EPS came in at -0.35 against a street estimate of -0.23 — a miss of 52.2%.

Key statistics

Market cap

$249.3M

Forward P/E

18.7

P/B

2.47

Book value

$2.24

EPS (TTM)

$-1.14

52-week high

$7.65

52-week low

$4.00

50-day MA

$5.77

200-day MA

$5.54

Beta

1.30

Analyst view

Analysts rate Abeona Therapeutics Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $18.88.

Shareholding

Insiders

10.96%

Institutions

74.90%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	17.96%
BlackRock Inc	5.86%
Cable Car Capital LLC	5.26%
AIGH Capital Management, LLC	5.22%
Vanguard Capital Management, LLC	3.87%
Resources Investment Advisors Inc	2.89%
Awm Investment Company Inc	2.60%
Geode Capital Management, LLC	2.21%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Abeona Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.